van BiesenW., WilliamsJ.D., CovicA.C., FanS., ClaesK., Lichodziejewska-NiemierkoM.; EuroBCM Study Group. Fluid status in peritoneal dialysis patients: the European Body Composition Monitoring (EuroBCM) study cohort.PLOS ONE2011; 6: e17148.
2.
van BiesenW., ClaesK., CovicA., FanS., Lichodziejewska-NiemierkoM., SchoderV.A multicentric, international matched pair analysis of body composition in peritoneal dialysis versus haemodialysis patients.Nephrol Dial Transplant2013; 28: 2620–8.
3.
YaoY.H., FuC.H., HoS.J., TsaiS.H., NgY.Y., ChuangC.L.Peritoneal dialysis as compared with hemodialysis is associated with higher overhydration but non-inferior blood pressure control and heart function.Blood Purif2012; 34: 40–7.
4.
KoningsC.J., KoomanJ.P., SchonckM., DammersR., CheriexE., Palmans MeulemansA.P.Fluid status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis.Perit Dial Int2002; 22: 477–87.
5.
WizemannV., WabelP., ChamneyP., ZaluskaW., MoisslU., RodeC.The mortality risk of overhydration in haemodialysis patients.Nephrol Dial Transplant2009; 24: 1574–9.
6.
O'LoneE.L., VisserA., FinneyH., FanS.L.Clinical significance of multi-frequency bioimpedance spectroscopy in peritoneal dialysis patients: independent predictor of patient survival.Nephrol Dial Transplant2014; 29: 1430–7.
7.
QuanL., XuY., LuoS.P., WangL., LeBlancD., WangT.Negotiated care improves fluid status in diabetic peritoneal dialysis patients.Perit Dial Int2006; 26: 95–100.
8.
Avila-DíazM., VenturaM.D., ValleD., Vicenté–MartínezM., García-GonzálezZ., CisnerosA.Inflammation and extracellular volume expansion are related to sodium and water removal in patients on peritoneal dialysis.Perit Dial Int2006; 26: 574–80.
9.
AteşK., NergizogluG., KevenK., SenA., KutlayS., ErtürkS.Effect of fluid and sodium removal on mortality in peritoneal dialysis patients.Kidney Int2001; 60: 767–76.
10.
DaviesS.J., PhillipsL., NaishP.F., RussellG.I.Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis.J Am Soc Nephrol2001; 12: 1046–51.
11.
BargmanJ.M., ThorpeK.E., ChurchillD.N. CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study.J Am Soc Nephrol2001; 12: 2158–62.
12.
KoningsC.J., KoomanJ.P., SchonckM., StruijkD.G., GladziwaU., HoorntjeS.J.Fluid status in CAPD patients is related to peritoneal transport and residual renal function: evidence from a longitudinal study.Nephrol Dial Transplant2003; 18: 797–803.
13.
KooH.M., DohF.M., KimC.H., LeeM.J., KimE.J., HanJ.H.Changes in echocardiographic parameters according to the rate of residual renal function decline in incident peritoneal dialysis patients.Medicine (Baltimore)2015; 94: e427.
ChanT.M., YungS.Studying the effects of new peritoneal dialysis solutions on the peritoneum.Perit Dial Int2007; 27(Suppl 2): S87–93.
16.
KawanishiK., HondaK., TsukadaM., OdaH., NittaK.Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis.Perit Dial Int2013; 33: 242–51.
17.
JohnsonD.W., BrownF.G., ClarkeM., BoudvilleN., EliasT.J., FooM.W.; balANZ Trial Investigators. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.J Am Soc Nephrol2012; 23: 1097–107.
18.
JohnsonD.W., BrownF.G., ClarkeM., BoudvilleN., EliasT.J., FooM.W.; balANZ Trial Investigators. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.Nephrol Dial Transplant2012; 27: 4445–53.
19.
WilliamsJ.D., TopleyN., CraigK.J., MackenzieR.K., PischetsriederM., LageC.; The Euro-Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.Kidney Int2004; 66: 408–18.
20.
MortierS., De VrieseA.S., Van de VoordeJ., SchaubT.P., Passlick-DeetjenJ., LameireN.H.Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration, and glucose degradation products.J Am Soc Nephrol2002; 13: 480–9.
21.
ChoY., JohnsonD.W., BadveS.V., CraigJ.C., StrippoliG.F., WigginsK.J.The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients.Kidney Int2013; 84: 969–79.
22.
SeoE.Y., AnS.H., ChoJ.H., SuhH.S., ParkS.H., GwakH.Effect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials.Perit Dial Int2014; 34: 724–31.
23.
Haag-WeberM., KrämerR., HaakeR., IslamM.S., PrischlF., HaugU.; behalf of the DIUREST Study Group. Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.Nephrol Dial Transplant2010; 25: 2288–96.
24.
OrtizA., WieslanderA., LindenT., SantamariaB., SanzA., JustoP.3,4-DGE is important for side effects in peritoneal dialysis what about its role in diabetes.Curr Med Chem2006; 13: 2695–702.
25.
DaviesS.J.Preserving residual renal function in peritoneal dialysis: volume or biocompatibility?Nephrol Dial Transplant2009; 24: 2620–2.
26.
Lichodziejewska-NiemierkoM., ChmielewskiM., DudziakM., RytaA., RutkowskiB.Hydration status of patients dialyzed with biocompatible peritoneal dialysis fluids.Perit Dial Int2016; 36: 257–61.
27.
GünalA.I., DumanS., OzkahyaM., TözH., AsçiG., AkçiçekF.Strict volume control normalizes hypertension in peritoneal dialysis patients.Am J Kidney Dis2001; 37: 588–93.
28.
KoningsC.J., KoomanJ.P., GladziwaU., van der SandeF.M., LeunissenK.M.A decline in residual glomerular filtration during the use of icodextrin may be due to underhydration.Kidney Int2005; 67: 1190–1.
29.
JansenM.A., HartA.A., KorevaarJ.C., DekkerF.W., BoeschotenE.W., KredietR.T. NECOSAD Study Group. Predictors of the rate of decline of residual renal function in incident dialysis patients.Kidney Int2002; 62: 1046–53.
30.
Van BiesenW., JörresA.Fluid overload and residual renal function in peritoneal dialysis: the proof of the pudding is in the eating.Kidney Int2014; 85: 15–7.
31.
McCaffertyK., FanS., DavenportA.Extracellular volume expansion, measured by multifrequency bioimpedance, does not help preserve residual renal function in peritoneal dialysis patients.Kidney Int2014; 85: 151–7.
32.
LindleyE.J., LopotF.The use of bioimpedance to aid volume assessment in dialysis patients.Kidney Int2015; 87: 240.
33.
MoisslU.M., WabelP., ChamneyP.W., BosaeusI., LevinN.W., Bosy-WestphalA. Body fluid volume determination via body composition spectroscopy in health and disease.Physiol Meas2006; 27: 921–33.
34.
LuoY.J., LuX.H., WoodsF., WangT.Volume control in peritoneal dialysis patients guided by bioimpedance spectroscopy assessment.Blood Purif2011; 31: 296–302.
35.
BassoF., Milan MananiS., CruzD.N., TeixeiraC., BrendolanA., NalessoF.Comparison and reproducibility of techniques for fluid status assessment in chronic hemodialysis patients.Cardiorenal Med2013; 3: 104–12.
